NeurologyLive Friday 5 — January 8, 2021


Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: How Pharmaceutical Innovation Is Saving the World

Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences, penned an op-ed praising the efforts of the medical and pharmaceutical communities for their swift action in developing vaccines in record time for COVID-19.

2: Michael Okun, MD: Importance of Disease-Based Registries

The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.

3: The Significance of 5-HT1F Agonist Approval

A discussion with Amaal Starling, MD, on the significance of the approval of a 5-HT1F agonist, with special consideration of the safety and efficacy from the respective clinical trial.

4: Out-of-Pocket Costs Steadily Increasing for Neurologic Care

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

5: Choosing Cannabidiol or Fenfluramine for Dravet

M. Scott Perry, MD, reviews how cannabidiol and fenfluramine are chosen for patients with Dravet syndrome based on concomitant medications and associated adverse events.

Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.